NEOS Investment Management LLC Acquires New Shares in Insmed Incorporated (NASDAQ:INSM)

NEOS Investment Management LLC bought a new position in shares of Insmed Incorporated (NASDAQ:INSM) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,626 shares of the biopharmaceutical company’s stock, valued at approximately $734,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Abel Hall LLC increased its position in shares of Insmed by 4.7% during the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 151 shares during the last quarter. Steward Partners Investment Advisory LLC raised its stake in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 163 shares during the period. M&T Bank Corp lifted its holdings in shares of Insmed by 5.6% in the 4th quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company’s stock worth $217,000 after acquiring an additional 166 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Insmed by 5.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 183 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Insmed by 3.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company’s stock valued at $446,000 after purchasing an additional 186 shares during the last quarter.

Insider Activity

In related news, CFO Sara Bonstein sold 1,066 shares of the business’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.72, for a total value of $67,925.52. Following the transaction, the chief financial officer now owns 118,863 shares in the company, valued at $7,573,950.36. The trade was a 0.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the sale, the insider now directly owns 97,083 shares of the company’s stock, valued at $7,766,640. The trade was a 48.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 550,957 shares of company stock valued at $42,992,528. 4.60% of the stock is currently owned by company insiders.

Insmed Stock Up 0.4 %

Shares of NASDAQ INSM opened at $77.99 on Monday. The business has a 50-day moving average of $78.18 and a two-hundred day moving average of $74.00. The company has a market capitalization of $14.12 billion, a price-to-earnings ratio of -13.95 and a beta of 1.28. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

INSM has been the subject of several research analyst reports. Morgan Stanley raised their price target on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Truist Financial raised their target price on Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a report on Friday, February 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Guggenheim restated a “buy” rating and issued a $101.00 price objective on shares of Insmed in a report on Tuesday, February 25th. Finally, Bank of America increased their target price on shares of Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $94.00.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.